Q3 EPS Forecast for Puma Biotechnology Lowered by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Analysts at Zacks Research dropped their Q3 2026 EPS estimates for Puma Biotechnology in a research report issued on Thursday, August 27th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings of $0.06 per share for the quarter, down from their previous forecast of $0.08. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q3 2027 earnings at $0.02 EPS.

Other analysts have also recently issued reports about the company. TD Cowen raised their price target on Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a report on Friday, August 7th. Weiss Ratings raised Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 21st. Finally, Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $6.00.

Puma Biotechnology Trading Up 2.6%

NASDAQ PBYI opened at $9.35 on Wednesday. The business’s 50 day moving average is $8.43 and its two-hundred day moving average is $7.47. Puma Biotechnology has a 12-month low of $4.30 and a 12-month high of $9.59. The stock has a market capitalization of $482.65 million, a price-to-earnings ratio of 17.98 and a beta of 1.24.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.15. The business had revenue of $56.50 million for the quarter, compared to analyst estimates of $53.00 million. Puma Biotechnology had a net margin of 11.50% and a return on equity of 20.76%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PBYI. Royal Bank of Canada boosted its position in shares of Puma Biotechnology by 244.5% in the 1st quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 3,066 shares in the last quarter. Legal & General Group Plc acquired a new position in Puma Biotechnology during the second quarter worth about $35,000. Cerity Partners LLC acquired a new position in Puma Biotechnology during the second quarter worth about $36,000. California State Teachers Retirement System lifted its holdings in shares of Puma Biotechnology by 110.2% in the second quarter. California State Teachers Retirement System now owns 4,898 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 2,568 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Puma Biotechnology by 39.7% in the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 2,290 shares in the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Insider Buying and Selling at Puma Biotechnology

In other news, Director Allison Dorval sold 11,610 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $7.20, for a total transaction of $83,592.00. Following the sale, the director owned 90,780 shares of the company’s stock, valued at $653,616. The trade was a 11.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alan H. Auerbach sold 44,058 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $8.26, for a total value of $363,919.08. Following the completion of the sale, the chief executive officer owned 7,261,671 shares in the company, valued at approximately $59,981,402.46. This represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 132,028 shares of company stock worth $1,006,711. Corporate insiders own 22.20% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a late?stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small?molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early?stage HER2-positive breast cancer.